Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

Published:2019-06-24 Issue:6 Volume:186 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Blombery Piers¹²³^ORCID,Birkinshaw Richard W.⁴⁵,Nguyen Tamia¹³,Gong Jia‐nan⁴⁵,Thompson Ella R.¹³,Xu Zhen⁴⁵,Westerman David A.¹²³,Czabotar Peter E.⁴⁵,Dickinson Michael²³,Huang David C.S.⁴⁵,Seymour John F.²³^ORCID,Roberts Andrew W.²⁴⁵⁶⁷

Affiliation:

1. Department of Pathology Peter MacCallum Cancer Centre Melbourne Australia

2. Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Australia

3. Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Australia

4. The Walter and Eliza Hall Institute of Medical Research Melbourne Australia

5. Department of Medical Biology University of Melbourne Melbourne Australia

6. Centre for Cancer Research University of Melbourne Melbourne Australia

7. Victorian Comprehensive Cancer Centre Melbourne Australia

Funder

Snowdome Foundation

Wilson Centre for Lymphoma Genomics, Vision Super

Leukaemia Lymphoma Foundation

Australian National Health and Medical Council

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16069

Reference10 articles.

1. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

2. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

3. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

4. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

5. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma;Journal of Experimental Medicine;2024-09-05

2. Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3‐mimetics using virtual tumors calibrated with cell viability assays;CPT: Pharmacometrics & Systems Pharmacology;2024-05-15

3. Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax;Exploration of Medicine;2024-05-10

4. Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma;American Journal of Hematology;2024-05-03

5. Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy;Blood;2024-05-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3